Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discovary Study: Darolutamide in AR-positive Salivary Gland Carcinoma
NCT05694819Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Apr 2020
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in salivary gland carcinoma (SGC), sponsored by National Cancer Center Hospital East. Started Apr 2020; status: completed.
02
Drugs
darolutamide
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT05694819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694819.